联系我们Contact us
1. 基本信息
品系名称 NOD. Prkdcscid Il2rgtm1 Vst Tg(Csf1p -IL3)Vst/Vst
常用名 hIL-3 NPG /Vst; hIL-3 NPG
背(bei)景 NOD-scid/NcrCrl
毛色(se) 白色(se)
品系(xi)建立：
采用转(zhuan)基因的方法，构建(jian)pCDNA3.1-Csf1p-IL3载体(ti)，将线性(xing)化Csf1p-IL3表达(da)(da)序列注射到(dao)NPG小鼠(shu)的原核中，在获得的后代中筛选(xuan)到(dao)合(he)适(shi)表达(da)(da)量的阳性(xing)小鼠(shu)。
在隔离器中，按照近交的(de)方式扩繁建立商品化的(de)hIL-3 NPG小鼠品系。
2. 表型
在(zai)NPG小鼠(shu)(shu)(shu)中(zhong)表(biao)达人(ren)(ren)的(de)(de)(de)hIL-3细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)因子。白细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)介素3刺激多(duo)能(neng)造血(xue)(xue)干细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)分(fen)(fen)化(hua)(hua)为(wei)髓(sui)系祖细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)。可以与表(biao)达人(ren)(ren)GM-CSF、M-CSF细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)因子的(de)(de)(de)NPG小鼠(shu)(shu)(shu)一起，在(zai)移植(zhi)人(ren)(ren)CD34+造血(xue)(xue)干细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)6-8周后，于(yu)外周血(xue)(xue)、骨(gu)髓(sui)、胸(xiong)腺和(he)脾脏(zang)以及包括肺和(he)肝在(zai)内的(de)(de)(de)非淋(lin)巴组织中(zhong)，形成稳定广泛(fan)的(de)(de)(de)髓(sui)系和(he)淋(lin)巴系细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)分(fen)(fen)化(hua)(hua)。在(zai)血(xue)(xue)液和(he)组织中(zhong)，可检测到粒细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)分(fen)(fen)化(hua)(hua)（嗜碱性(xing)粒细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)、中(zhong)性(xing)粒细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)和(he)肥(fei)大细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)），抗原呈(cheng)递细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)分(fen)(fen)化(hua)(hua)（树突状细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)和(he)巨噬细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)）和(he)调(diao)节性(xing)T细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)群体等(deng)。表(biao)达人(ren)(ren)M-CSF、GM-CSF和(he)人(ren)(ren)IL-3细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)因子与Hu-NPG人(ren)(ren)源(yuan)化(hua)(hua)小鼠(shu)(shu)(shu)相比，人(ren)(ren)类(lei)造血(xue)(xue)干细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)（hsc）的(de)(de)(de)整体植(zhi)入水平(ping)更高(gao)，分(fen)(fen)化(hua)(hua)细(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)种(zhong)类(lei)更多(duo)。
3. 应用领域
-人源化(hua)和(he)癌(ai)症(zheng)治疗(liao)
-人体过敏反应(ying)模型，免疫、造血移植重建模型
-再生医学
-感染(ran)性疾病
-生(sheng)医学
4. 参(can)考文献
（1）Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, Ogura T, Ida-Tanaka M, Suemizu H, Nunomura S, Ra C, Mori A, Aiso S, Ito M. (2013) Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol.191(6):2890-9.
（2）Wunderlich M; Chou FS; Link KA; Mizukawa B; Perry RL; Carroll M; Mulloy JC. 2010. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24(10):1785-8.
（3）Billerbeck E; Barry WT; Mu K; Dorner M; Rice CM; Ploss A. 2011. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R{gamma}null humanized mice. Blood 117(11):3076-86.
（4）Coughlan AM; Harmon C; Whelan S; O'Brien EC; O'Reilly VP; Crotty P; Kelly P; Ryan M; Hickey FB; O'Farrelly C; Little MA. 2016. Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells Dev 25(7):530-41.
